SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: Raul Prytog who wrote (929)5/19/1999 9:20:00 PM
From: Investor Dave  Read Replies (1) | Respond to of 998
 
Hi all,

It appears that Provigil is going to be the revenue producing drug for Cephalon. The approval of Mytrophin may help the bottom line some. But, I don't think its approval will have much effect on Cephelon's stock price. It appears to me that the FDA has been reviewing Myotrophin's results for what seems a lifetime.

Any input on this?

Dave



To: Raul Prytog who wrote (929)5/19/1999 10:46:00 PM
From: Wally  Respond to of 998
 
Frankly, I wouldn't bet the ranch against MYO being approved. It's far from a wonder drug, but then again, it beats the hell out of nothing.
IMO, the heart of the issue is whether or not Cephalon has learned that they can't manhandle the FDA.
My guess is that there's been a great deal of soul-searching - perhaps some statesmanship to soften the politics.
I sold out at about 8 bucks - obviously, it was a mistake - perhaps a big one.

Wally


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News